Forty Seven Inc.

Biotech and pharma companies invest significant resources in the presentation and promotion of their data at medical conferences. This is because wider appreciation of their promising experimental dru

Gilead Sciences, Inc. ’s first-in-class immunotherapy candidate, magrolimab, has been hit with a partial clinical hold from the US Food and Drug Administration in acute myeloid leukemia (AML), less th

Months after the US Food and Drug Administration lifted a hold on Gilead Sciences, Inc. ’s CD47-targeting monoclonal antibody magrolimab, studies of the drug in acute myeloid leukemia (AML) have once

Glenmark Pharmaceuticals Limited ’s innovation spin-out, Ichnos Sciences, Inc. , has signaled momentum for its promising early stage oncology assets and committed alongside to strive to align its cos